AB2Bio is a biotech company dedicated to developing “best in class” therapies for severe inflammatory diseases. While inflammation is a natural defense mechanism, when dysregulated and persistent it becomes the root cause of serious conditions such as primary HLH, Macrophage Activation Syndrome, Still’s Disease, and others.

AB2Bio is developing Tadikinig alfa, an IL-18 binding protein (IL-18bp), for severe hyperinflammatory conditions like primary HLH. Tadikinig alfa has successfully completed a Phase III trial in primary HLH and is currently progressing toward BLA submission. AB2Bio is also exploring the potential of IL-18bp in other hyperinflammatory conditions, aiming to establish a new standard of care for these significant unmet medical needs.